1. 1319 A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone. (September 2015) Authors: Bonnet, C.; Thomas-Schoemann, A.; Boudou-Rouquette, P.; Huillard, O.; Carton, E.; Cessot, A.; Morin, B.; Giroux, J.; Tlemsani, C.; Arrondeau, J.; Vidal, M.; Blanchet, B.; Alexandre, J.; Goldwasser, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients. (September 2015) Authors: Carton, E.; Noe, G.; Huillard, O.; Golmard, J.L.; Giroux, J.; Cessot, A.; Peyromaure, M.; Zerbib, M.; Narjoz, C.; Thomas, A.; Vidal, M.; Goldwasser, F.; Blanchet, B.; Alexandre, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. (February 2017) Authors: Carton, E.; Noe, G.; Huillard, O.; Golmard, L.; Giroux, J.; Cessot, A.; Saidu, N.E.B.; Peyromaure, M.; Zerbib, M.; Narjoz, C.; Guibourdenche, J.; Thomas, A.; Vidal, M.; Goldwasser, F.; Blanchet, B.; Alexandre, J. Journal: European journal of cancer Issue: Volume 72(2017) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗